Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Veracyte reports record Q4 revenue and strategic growth initiatives

Veracyte's Q4 performance reflects strong financials and product advancements, positioning the company for continued growth.
While facing challenges in cost management and operational transitions, Veracyte remains proactive in addressing market demands.
Opportunities for revenue growth and market expansion through new product developments and reimbursement progress are key focus areas.
Overall, Veracyte's strategic initiatives and market positioning suggest a promising outlook for future success.

Veracyte reports robust Q1 earnings, eyes global expansion opportunities

Veracyte's strong Q1 performance was driven by Afirma and Decipher tests, despite challenges in the biopharma business.
The company's focus on global expansion, product enhancement, and evidence generation positions it well for future growth.
Challenges in margins and customer spending require strategic adjustments, but Veracyte remains optimistic about its investment levels.
ESG efforts and commitment to patient outcomes underscore Veracyte's dedication to transforming healthcare and stakeholder value.

Veracyte reports strong Q2 earnings, raises 2023 revenue outlook

Veracyte's Q2 performance reflects robust revenue growth, operational efficiency, and increased market confidence.
While facing challenges in the biopharma segment and manufacturing transitions, the company is well-positioned to capitalize on market opportunities.
With raised revenue projections, strong product performance, and strategic focus areas, Veracyte is poised for continued growth and market expansion.

Veracyte (VCYT) reports robust Q3 performance and eyes market expansion

Veracyte (VCYT) delivered strong financial results in Q3 2023, driven by core testing business growth and strategic partnerships.
Despite supply chain challenges, the company remains focused on market expansion, operational optimization, and cash flow generation.
With a positive outlook for 2024 and a focus on evidence generation and market penetration, Veracyte is poised for continued growth and transformation in cancer care.

Veracyte reports record 2023 revenue, eyes market expansion in 2024

Veracyte's strong 2023 performance sets the stage for continued growth in 2024.
Balancing short-term challenges with long-term opportunities for market expansion.
Strategic acquisitions and product developments position Veracyte well in evolving markets.
Maintaining financial guidance and operational focus key to sustained success.

Veracyte's Q1 2024 earnings call showcased strong revenue growth driven by Decipher Prostate and Afirma.
The company raised total revenue guidance for 2024 and highlighted interest from biopharma in data projects.
While facing challenges like FDA LDT regulation, Veracyte remains focused on existing growth drivers and global expansion.
Excitement surrounds the company's growth trajectory and opportunities in Decipher, MRD testing, and new cancer challenges.

Veracyte reports stellar Q2 results, eyes revenue growth opportunities

Veracyte's Q2 2024 performance reflects robust revenue growth, driven by strong testing revenue and strategic initiatives focused on market expansion and innovation.
Despite facing seasonal revenue fluctuations, the company remains optimistic about achieving its raised revenue guidance for 2024, underpinned by the growth in testing business.
The emphasis on profitability, cash generation, and revenue growth through Decipher and Afirma positions Veracyte well for sustained financial success and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptive Biotechnologies

Fate Therapeutics

Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.

3 Cathie Wood Stocks for the Future

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

Veracyte, Inc. (NASDAQ:VCYT ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Tina Nova - President of CLIA Business Giulia Kennedy - Global Chief Scientific Officer and Chief Medical Officer Conference Call Participants Brian Weinstein - William Blair Puneet Souda - SVB Securities Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Andrew Cooper - Raymond James Mike Matson - Needham & Company Mason Carrico - Stephens Paul Knight - KeyBanc Operator Good day, and thank you for standing by. Welcome to the Veracyte Second Quarter 2022 Financial Results Conference Call [Operator Instructions].

Veracyte, Inc. (VCYT) CEO Marc Stapley on Q2 2022 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2022. “Our second quarter results reflect our continued focus on execution, and as a result, our portfolio delivered robust revenue growth,” said Marc Stapley, Veracyte's chief executive officer. “In addition, we significantly expanded the library of clinical evidence demonstrating the performance and utility of our genomic tests and biopharma offer

Veracyte Announces Second Quarter 2022 Financial Results

Veracyte appears to be an intriguing pick for growth investors to compound their wealth over the long run.

3 Reasons to Buy This Sizzling Growth Stock

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new clinical validation data published online in Thyroid show that the company's RNA sequencing-based Afirma Medullary Thyroid Cancer (MTC) Classifier demonstrated high sensitivity and specificity in identifying MTC among pre-operative thyroid nodule fine needle aspiration (FNA) biopsy samples. The findings suggest that the genomic test may enable more timely diagnosis of this rare but aggressive fo

Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid

Shares of cancer diagnostics concern Veracyte, Inc. have shot up approximately 60% over the past month, snapping a deep decline. That said, valuations were stratospheric (22.6x FY21 sales at their peak), but shares of unprofitable Veracyte now trade at just under seven times FY22E sales net of cash.

Veracyte: Fading The Rally

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2022 after the close of market on Tuesday, August 2, 2022. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link:

Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Data published in PLOS ONE show Veracyte's Percepta Genomic Sequencing Classifier can improve lung cancer diagnosis in certain lung nodule patients.

New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte's Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis

The average of price targets set by Wall Street analysts indicates a potential upside of 41.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 41% Upside in Veracyte (VCYT): Here's What You Should Know

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has been named a Bay Area Top Workplace for the ninth consecutive year. The annual award is based solely on employee feedback gathered through an anonymous, third-party survey administered by Energage, LLC. The survey measures 15 culture drivers that are critical to organizational success, including alignment, execution, and connection. On average, fewer than three

Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that findings from a new meta-analysis provide real-world evidence that the Afirma Genomic Sequencing Classifier (GSC) can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules and that, when the test deems a nodule as suspicious, the patient's risk of malignancy is consistent, and higher than that reported in the test's original clinical validation (CV) study. The findings we

New Data Show Strong Performance of Veracyte's Afirma GSC in Real-World Clinical Practice

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Data Reinforce Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier for Informing Treatment of Men with Prostate Cancer Progression

Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that new data published online in The Lancet Oncology suggest that the company's Immunoscore Immune Checkpoint (IC) assay may identify patients with metastatic colorectal cancer (mCRC) who are likely to benefit from the addition of immune checkpoint inhibitor (ICI) therapy to standard first-line treatment. The findings are from the randomized, controlled, phase II AtezoTRIBE trial, a multicenter Italian

Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from a large, population-based study reinforce the clinical utility of the Decipher Prostate genomic classifier. The findings, which will be shared for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, suggest that the Decipher Prostate tests are helping to guide prostate cancer treatment decisions and improve patient care. “This is the first study link

New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today new data from a clinical research study demonstrating the ability of its Immunoscore Immune Checkpoint (IC) assay to predict which patients with metastatic non-small cell lung cancer (NSCLC) may benefit from immune checkpoint inhibitors (ICIs). The findings will be shared in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 6 at 1:15 p.m. CDT.

Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay's Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences. Veracyte will present at the William Blair 42nd Annual Growth Stock Conference on Wednesday, June 8, and will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Monday, June 13. Event: William Blair 42nd Annual Growt

Veracyte to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden and whether they are considered high risk for lung cancer based on U.S. Preventive Services Task Force (USPSTF) screening criteria. The findings were presented today at the American Thoracic Society 2022 International Confer

Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test's Clinical Performance and Utility in Lung Cancer Risk Assessment

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Updated AUA/ASTRO Guideline Includes Use of Genomic Tests, Including Decipher Prostate, for Men with Localized Prostate Cancer

Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer

Veracyte has seen a real share price reversal over the past year. The company has been a momentum name, but not necessarily a pandemic beneficiary.

Veracyte: Not A Healthy Diagnosis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that six abstracts demonstrating the ability of its genomic and immuno-oncology diagnostic tests and technology to improve outcomes for cancer patients will be shared at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place in person and virtually from June 3-7, in Chicago. “The findings being presented at the ASCO annual meeting expand the performance

Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that new consensus data from a survey of leading breast cancer oncologists in Europe suggest the importance of gene expression profile (GEP) testing in guiding treatment decisions for women with early-stage breast cancer. The findings, from the PROCURE study, were presented today at the European Society of Medical Oncology (ESMO) Breast Cancer 2022, taking place May 3-5 in Berlin, Germany. The PROCURE st

Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022

Veracyte, Inc. (NASDAQ:VCYT ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial Officer Giulia Kennedy – Chief Scientific & Medical Officer Tina Nova – General Manager of Thyroid & Urologic Cancer Sheila Goldman – Director of Investor Relations Conference Call Participants Brian Weinstein – William Blair David Hein – Goldman Sachs Mason Carrico – Stephens Inc. Tejas Savant – Morgan Stanley Paul Knight – KeyBanc Joseph Stringer – Needham & Company Puneet Souda – SVB Securities Operator Good afternoon, ladies and gentlemen, and welcome to Veracyte's First Quarter 2022, financial results conference call. At this time, all participants are in a listen-only mode.

Veracyte, Inc. (VCYT) CEO Marc Stapley on Q1 2022 Results - Earning Calls Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2022. "I am extremely pleased with our team's strong results in the first quarter,” said Marc Stapley, Veracyte's chief executive officer. “Last year we assembled the critical elements needed to drive near and long-term growth, including our acquisitions of Decipher Biosciences and HalioDx, complementing our prior acquisition of the nCounter diagnos

Veracyte Announces First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that an updated clinical practice guideline highlights the role of the Envisia Genomic Classifier in the diagnosis of idiopathic pulmonary fibrosis (IPF). The document, Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline, appears online in the American Journal of Respiratory and Critical Care Medicine (AJRCCM). A

News for Veracyte Stock (VCYT)